C. Pozzan
University of Padua
Survival analysisCancerInternal medicineSurgeryPathologyOncologyAntigenHypoxia-inducible factorsChemistryProspective cohort studyLiver cancerVascular endothelial growth factorCirrhosisCarcinomaHepatocellular carcinomaSorafenibEsophageal cancerSingle nodeSurvival predictorsHepatologyCancer researchMedicineBiomarker (medicine)Gastroenterology
21Publications
5H-index
134Citations
Publications 21
Newest
#1G. Maddalo (St Mary's Hospital)H-Index: 8
#2Matteo FassanH-Index: 66
Last. Fabio FarinatiH-Index: 69
view all 12 authors...
GOAL: To evaluate the potential role of the determination of the immunocomplexed form of squamous cell carcinoma antigen [SCCA-immunoglobulin (Ig)M] for the screening of Barrett esophagus (BE) and esophageal adenocarcinoma (EAC). BACKGROUND: The cost-effectiveness of surveillance in BE is still debated and the use of biomarkers in screening and surveillance still not recommended. No information is available regarding SCCA-IgM determination in BE. STUDY: SCCA-IgM levels were determined (enzyme-li...
Source
Source
#1A. Meneghetti (UNIPD: University of Padua)
#2G. Peserico (UNIPD: University of Padua)H-Index: 4
Last. Fabio Farinati (UNIPD: University of Padua)H-Index: 69
view all 10 authors...
Source
#1Francesca Murer (UNIPD: University of Padua)H-Index: 2
#2C. Pozzan (UNIPD: University of Padua)H-Index: 5
Last. Fabio Farinati (UNIPD: University of Padua)H-Index: 69
view all 4 authors...
Source
#1Alessandro Cucchetti (UNIBO: University of Bologna)H-Index: 66
#2Franco Trevisani (UNIBO: University of Bologna)H-Index: 38
Last. Matteo ValerioH-Index: 1
view all 79 authors...
Summary Background Hepatocellular carcinoma (HCC) causes premature death and loss of life expectancy worldwide. Its primary and secondary prevention can result in a significant number of years of life saved. Aim To assess how many years of life are lost after HCC diagnosis. Methods Data from 5346 patients with first HCC diagnosis were used to estimate lifespan and number of years of life lost after tumour onset, using a semi-parametric extrapolation having as reference an age-, sex- and year-of-...
Source
Source
#1C. Pozzan (UNIPD: University of Padua)H-Index: 5
#2M.A. Di Vasto (UNIPD: University of Padua)
Last. Fabio Farinati (UNIPD: University of Padua)H-Index: 69
view all 6 authors...
Source
#1Veronica VaninH-Index: 8
#2A. ImondiH-Index: 3
Last. Fabio FarinatiH-Index: 69
view all 10 authors...
Source
Source
#1Fabio Piscaglia (UNIBO: University of Bologna)H-Index: 80
#2G. Svegliati Baroni (Marche Polytechnic University)H-Index: 4
Last. D. MalagottiH-Index: 2
view all 45 authors...
the AFP, the poorer the prognosis, but no good evidence in the literature exists on the minority of patients with HCC who do not secrete AFP. Our aim was to analyse this sub-group of patients from a cohort with advanced HCC treated with Sorafenib, and assess survival outcomes. Methods: Consecutive patients with a confirmed diagnosis of HCC as per AASLD criteria, treated with Sorafenib at Queen Elizabeth Hospital Birmingham UK, between April 2009 and March 2014 were included in the analysis. We t...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.